Explore

Trendline Trendline
Novastra Therapeutics Appoints New CFO Amid Global Clinical Development Efforts

Novastra Therapeutics Appoints New CFO Amid Global Clinical Development Efforts

Novastra Therapeutics Appoints New CFO Amid Global Clinical Development Efforts
Reuters Reuters
Regeneron drops after skin cancer treatment fails late-stage trial

Regeneron drops after skin cancer treatment fails late-stage trial

By Christy Santhosh May 18 (Reuters) - Regeneron's shares fell 12% in morning trade on Monday after the company's experimental treatment missed the main goal in a late-stage trial for patients with a type of skin cancer.
Trendline Trendline
Novastra Therapeutics Appoints New CFO to Propel Global Clinical Development

Novastra Therapeutics Appoints New CFO to Propel Global Clinical Development

Novastra Therapeutics Appoints New CFO to Propel Global Clinical Development
Trendline Trendline
SpaceX Plans Accelerated IPO to Raise $75 Billion, Targeting Nasdaq Debut

SpaceX Plans Accelerated IPO to Raise $75 Billion, Targeting Nasdaq Debut

SpaceX Plans Accelerated IPO to Raise $75 Billion, Targeting Nasdaq Debut
Trendline Trendline
Parabilis and Regeneron Partner to Develop Novel Antibody-Helicon Conjugates

Parabilis and Regeneron Partner to Develop Novel Antibody-Helicon Conjugates

Parabilis and Regeneron Partner to Develop Novel Antibody-Helicon Conjugates
Trendline Trendline
Palatin Technologies to Transition Stock Listing to Nasdaq, Aiming for Greater Visibility

Palatin Technologies to Transition Stock Listing to Nasdaq, Aiming for Greater Visibility

Palatin Technologies to Transition Stock Listing to Nasdaq, Aiming for Greater Visibility
Trendline Trendline
Cerebras Prices IPO, Raises $5.55 Billion Amid AI Chip Interest

Cerebras Prices IPO, Raises $5.55 Billion Amid AI Chip Interest

Cerebras Prices IPO, Raises $5.55 Billion Amid AI Chip Interest
Trendline Trendline
Inmune Bio to Release Year-End 2025 Financial Results, Impacting Investor Sentiment

Inmune Bio to Release Year-End 2025 Financial Results, Impacting Investor Sentiment

Inmune Bio to Release Year-End 2025 Financial Results, Impacting Investor Sentiment
Trendline Trendline
SpaceX Accelerates IPO Timeline, Aiming for Nasdaq Listing by June

SpaceX Accelerates IPO Timeline, Aiming for Nasdaq Listing by June

SpaceX Accelerates IPO Timeline, Aiming for Nasdaq Listing by June
Trendline Trendline
Contineum Therapeutics Grants Stock Options to New Employee Under Nasdaq Rule

Contineum Therapeutics Grants Stock Options to New Employee Under Nasdaq Rule

Contineum Therapeutics Grants Stock Options to New Employee Under Nasdaq Rule
Trendline Trendline
SpaceX Plans IPO with $1.75 Trillion Valuation, Aiming for June Launch

SpaceX Plans IPO with $1.75 Trillion Valuation, Aiming for June Launch

SpaceX Plans IPO with $1.75 Trillion Valuation, Aiming for June Launch
Trendline Trendline
Cerebras IPO Raises $5.55 Billion, Highlights Growing Interest in AI Chip Technology

Cerebras IPO Raises $5.55 Billion, Highlights Growing Interest in AI Chip Technology

Cerebras IPO Raises $5.55 Billion, Highlights Growing Interest in AI Chip Technology